BBIO
BridgeBio Pharma, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -5.0% ·
share flow -1.6% ·
net new positions -10.5%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 132 | +3 | 120.71M | $8.69B | +10 | −8 |
| Q1 2026 | 133 | +3 | 129.51M | $9.40B | +8 | −6 |
| Q4 2025 | 129 | +2 | 135.35M | $9.88B | +4 | −1 |
| Q3 2025 | 19 | -1 | 71.67M | $3.72B | — | −2 |
| Q2 2025 | 18 | -1 | 70.97M | $3.06B | +1 | −2 |
| Q1 2025 | 16 | +3 | 40.50M | $1.40B | +3 | — |
| Q4 2024 | 13 | 0 | 40.68M | $1.12B | +1 | −1 |
| Q3 2024 | 12 | -1 | 35.94M | $914.95M | — | −1 |
| Q2 2024 | 13 | — | 36.42M | $922.50M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 16.83M | +2.1% | $874.26M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | Viking Global Investors ✦ | 15.98M | -13.9% | $829.89M | 2.2% | ▼ Trim | 6 | SEC ↗ |
| 3 | BlackRock ✦ (passive) | 14.41M | +1.1% | $748.52M | 0.0% | ▲ Add | 2 | SEC ↗ ×18 |
| 4 | State Street Global Advisors ✦ (passive) | 5.61M | -4.9% | $291.19M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (passive) | 3.91M | +6.2% | $203.11M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | Two Sigma Investments ✦ | 2.33M | -0.4% | $120.97M | 0.2% | ▼ Trim | 6 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 2.25M | +8.2% | $117.01M | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 8 | Goldman Sachs Group ✦ | 2.21M | — | $114.74M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 9 | Fidelity (FMR) ✦ | 1.70M | -16.1% | $88.34M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 10 | T. Rowe Price ✦ | 1.57M | +63.1% | $81.42M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | Morgan Stanley ✦ | 1.05M | — | $54.79M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 12 | Wellington Management ✦ | 1.02M | +1698.5% | $52.94M | 0.0% | ▲ Add | 6 | SEC ↗ ×7 |
| 13 | Adage Capital Partners ✦ | 944.85K | +213.5% | $49.08M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 14 | JPMorgan Chase ✦ | 588.23K | — | $30.55M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 15 | PRIMECAP Management ✦ | 576.37K | -2.1% | $29.94M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | Renaissance Technologies ✦ | 322.25K | +31.0% | $16.74M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | Millennium Management ✦ | 170.44K | -72.5% | $8.85M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 18 | Marshall Wace ✦ | 101.24K | -76.0% | $5.26M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 98.83K | -37.4% | $5.13M | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Norges Bank | $84.49M | was 0.0% |
| Citadel Advisors | $14.35M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 15.30K shares, $1,136 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 1.28K sh · $88,980
Officer, Director · 8.72K sh · $601,868
Officer, Director · 1.80K sh · $152,436
Officer, Director · 100 sh · $8,565
Officer, Director · 8.10K sh · $679,256
Officer, Director · 1.90K sh · $154,184
Officer, Director · 17.28K sh · $1.42M
Officer, Director · 14.60K sh · $1.21M
Officer, Director · 1.20K sh · $100,444
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
4.2% of class · View original SEC filing ↗
5.0% of class · View original SEC filing ↗